Hemab Therapeutics, a clinical-stage biotech company focused on blood coagulation therapies, completed its upsized initial public offering (IPO) by selling 19,262,500 shares at $18 each, including full exercise of underwriters' options. The IPO raised approximately $346.7 million in gross proceeds. Hemab's shares began trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol COAG. The funds will support Hemab's development of innovative treatments for bleeding and thrombotic disorders, including therapies for Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.
Intertape Polymer Corp (IPG) has introduced a new PCR Air Pillow Film made with 50% recycled materials, including 35% post-consumer recycled content. This high-performance packaging film is designed to help companies meet sustainability goals without...
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
